Ultragenyx Pharmaceutical Inc.
RARE Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$15.65
KIRA · Stoqly’s AI analyst, in plain words
- Ultragenyx Pharmaceutical Inc. had $673M of revenue in fiscal 2025, up 20.2% on the year before. Over five years, revenue changed +19.9% a year on average.
- Its operating margin was −79.5%, up 16.2 pts: of every 100 in sales, about −79 is left after running the business.
- Ultragenyx Pharmaceutical Inc. lost $575M in fiscal 2025.
- Free cash flow was −$472M in fiscal 2025, −70.1% of revenue.
Market cap
$1.6B
P/E
—
Revenue
$673M
Net income
−$575M
Free cash flow
−$472M
Operating margin
−79.5%
Ultragenyx Pharmaceutical Inc. in 30 seconds · fiscal 2025
Are sales growing?
+20.2%
Yes. Sales grew 20.2% last year.
Does it make a profit?
−85.4%
No. It lost money last year.
Does profit turn into cash?
−70.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ultragenyx Pharmaceutical Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 18, 2026
- Legal name
- Ultragenyx Pharmaceutical Inc.
- CIK
- 0001515673
Ultragenyx Pharmaceutical Inc. · RARE
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $351M | $363M | $434M | $560M | $673M |
| Revenue growth | 29.7% | 3.4% | 19.5% | 29.0% | 20.2% |
| Operating margin | −108.6% | −178.6% | −131.1% | −95.7% | −79.5% |
| Net income | −$454M | −$707M | −$607M | −$569M | −$575M |
| Net margin | −129.2% | −194.7% | −139.9% | −101.6% | −85.4% |
| Diluted EPS | −$6.70 | −$10.12 | −$8.25 | −$6.29 | −$5.83 |
| Cash | |||||
| Cash from operations | −$339M | −$380M | −$475M | −$414M | −$466M |
| Capital expenditure | $73.1M | $116M | $44.0M | $7.0M | $6.0M |
| Free cash flow | −$412M | −$497M | −$519M | −$421M | −$472M |
| FCF margin | −117.2% | −136.7% | −119.6% | −75.2% | −70.1% |
| Share count change | 11.4% | 3.1% | 5.1% | 23.1% | 9.0% |
| Debt and strength | |||||
| Cash and short-term investments | $740M | $748M | $578M | $610M | $680M |
| Shareholders' equity | $923M | $352M | $275M | $255M | −$80.0M |
| Current ratio | 4.7x | 3.4x | 2.6x | 2.4x | 2.5x |
| Returns and quality | |||||
| Return on equity | −43.7% | −111.0% | −193.6% | −214.7% | −657.1% |
| Return on tangible equity | −60.7% | −479.6% | −943.7% | −1,724.2% | — |
| Piotroski F-score | 2 | 2 | 3 | 3 | 4 |
| Altman Z'' | −1.6 | −5.7 | −7.7 | −8.7 | −9.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.8M
9 insiders
Of sales under plans
35%
$1.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ultragenyx Pharmaceutical Inc. · RARE
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $15.65 a share, the company is worth $1.6B.
Source: SEC EDGAR XBRL filings (CIK 0001515673). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.